Pharma companies are weighing how a drug’s IP location could impact tariffs
Over the past few months, several biopharma companies like GSK, Merck, Alnylam and BioMarin have said they are monitoring how the location of their drugs’ intellectual property could be relevant to President Donald Trump’s forthcoming ...
Over the past few months, several biopharma companies like GSK, Merck, Alnylam and BioMarin have said they are monitoring how the location of their drugs’ intellectual property could be relevant to President Donald Trump’s forthcoming ...
